AN2 Therapeutics (ANTX) The Citizens JMP Life Sciences Conference 2025 summary

Novel drug development and pipeline overview

• Two novel compounds target previously unaddressed antibacterial and antiparasitic pathways, leveraging boron chemistry for rapid development and strong IP positioning.

• Expansion into oncology with promising boron-based candidates, including ENPP1 and PI3Kα, aiming for best-in-class potential and unique binding profiles.

• Multiple projects in the pipeline, with sufficient cash runway projected through 2028 to support ongoing and new developments.

Chagas disease program

• Oral candidate AN2-502998 (998) targets Chagas disease, a neglected condition affecting 7 million globally, with 300,000+ cases in the U.S.

• Demonstrated 100% cure in non-human primate models; phase I to begin in Australia, phase II planned for Bolivia and Latin America next year.

• Eligible for orphan drug status and a priority review voucher; commercial strategy focuses on test-and-treat and awareness in high-risk populations.

• Regulatory path includes phase II and a single pivotal phase III, with rapid patient recruitment expected.

Melioidosis and epetraborole programs

• IV epetraborole for melioidosis supported by an $18M NIH grant, advancing to phase II proof-of-concept in the second half of the year.

• Disease is a national security concern with high mortality; drug shows superior efficacy in animal models and is expected to reduce mortality.

• Commercial potential includes endemic country sales and government stockpiling; PRV anticipated.